TriReme Medical Inc. completed its $17 million Series D financing round.
Bio*One Capital PTE LTD led the financing; current investors Three Arch Partners and Adams Street Partners also contributed "strong support," according to Singapore-based Bio*One’s parent company EDB Investments PTE LTD.
The funding will support TriReme‘s product commercialization and development efforts in Asia, according to EDBI.
"This investment will allow us to ramp up our commercial activities worldwide, continue to develop internal R&D programs and pursue key regulatory approvals for our products in large markets such as the U.S., Japan and China,” CEO Eitan Konstantino said.
The Pleasanton, Calif.-based company develops balloon and stent-based therapies for for the treatment of coronary and peripheral artery disease.
